News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (343 of 400). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (15 of 400). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (42 of 400). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 291 of 400 items have one.
At-home injection version of Alzheimer’s drug now available in US
In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. …
Read at Alzheimer's News Today → Archived copy (2 Oct 2026), Internet ArchiveFDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. …
Read at Alzheimer's News Today →Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.
Last updated